Analog Devices, Inc. (NASDAQ: ADI) announced that ADI's Sensinel cardiopulmonary management (CPM) system has been certified by the US Food and Drug Administration (FDA) 510 (K) and was officially launched.This compact wearable device is a non -invasive remote management system that can monitor cardiopulmonary physiological data and is used to manage chronic diseases such as heart failure.This is the first FDA certification that ADI has found in 59 years.

Patrick O'doherty, senior vice president of ADI Digital Medical Health Health, said: "Since the establishment of the company, ADI has been committed to accelerating breakthrough innovation and using innovative products to enrich people's lives. Advanced technology, combined with the algorithm designed under the guidance of heart disease experts, we have successfully developed the Sensinel CPM system, which can accurately evaluate the daily health status of patients with congestive heart failure. This service -oriented innovative product not only not only It is possible to open up billions of dollars of new markets for ADI companies, and it can improve patient nursing effects, optimize the workflow of clinicians, and effectively reduce medical costs. "

At present, more than 6 million Americans suffer from heart failure. It is expected that by 2030, this number will increase to nearly 8 million.At present, heart failure will bring about $ 30 billion in medical expenses to Americans each year. It is expected that by 2030, this cost will climb to nearly 70 billion US dollars, of which about 80%are hospitalized treatment costs.Some previously launched solutions that monitors similar health indicators have proven to reduce the hospitalization rate.However, these solutions are usually either invasive, or the monitoring data is not accurate and specific, and cannot have a significant impact clinically.Accurate and timely data is important, which allows the medical team to predict and intervene in advance, so as to avoid patients paying expensive hospitalization costs due to heart failure.

The Sensinel CPM system is a new generation of solution for cardiopulmonary disease management such as heart failure.It has a series of physiological indicators monitoring functions that can assist the medical team earlier, more effective, and more accurate to remotely manage chronic diseases.Patients can wear ADI's Sensinel CPM wearable device, and only need to be worn for three to five minutes in the family care environment.After wearing, the device will collect patients' cardiopulmonary health data, and automatically upload data to the Sensinel CPM cloud platform of ADI through the honeycomb link (no patient needs to be connected by the Internet), and use ADI's Sensinel CPM intelligent algorithm to further in the clouds to further further use Analysis and processing.

Dr. Sean Pinney, Director of Cardiology, Mount Sinai MorningSide, New York City, said: "For clinicians, the physiological changes of patients as early as possible are the key to avoiding patients from admission to patients. The CPM system is a highly accurate, repeated and reliable solution, which helps improve our foresight of the development of the symptoms, so as to better care for patients. "

Dr. Venu Gopinathan, Academician and ADI Medical Product Management Director of ADI and ADI Medical Products Management, said: "When managing chronic diseases such as heart failure, it is very important to adjust the treatment measures early to control the condition and avoid hospitalization. At present, other non -invasive solutions cannot provide enough provision Specific data cannot meet the needs of clinical doctors to effectively conduct early intervention. The new cardiopulmonary management system we develop can seamlessly integrate into the nursing workflow. By conducting a variety of physiological indicators to help the medical team make accurate clinical decisions as soon as possible, and at the same time avoid it avoided The problem of information overload. "

Adi's Sensinel CPM system is now available.For more information, visit Sensinel.analog.com/.

###

About Sensinel by Analog Devices

Senseless by Analog Devices is a new wearable medical health series that is designed to fundamentally change the management of chronic diseases and allow patients to improve the quality of life in a affordable manner.The first product of this series Sensinel CPM system is a non -invasive family care solution that can monitor the management of cardiopulmonary physiological data and is used to manage chronic diseases such as heart failure.Analog Devices, which launched the Sensinel series, is a world -leading semiconductor company with more than 50 years of experience in the medical and health industry. Especially in the technical fields such as testing, measurement, calculation, connection, and power, it has promoted to accelerate the breakthrough innovation of human beings. , Make our lives and world more colorful.

About ADI

Analog Devices, Inc. (NASDAQ: ADI) is the world's leading semiconductor company. It is committed to setting up a bridge between the real world and the digital world to achieve breakthrough innovation in the intelligent edge field.ADI provides solutions that combine simulation, digital and software technology to promote the sustainable development of digital factories, automobiles and digital medical care, respond to climate change challenges, and build a reliable interconnection between people and the world.ADI revenue in fiscal 2023 more than $ 12 billion, and about 26,000 employees around the world.Together with 125,000 customers around the world, ADI helps innovators to continue to surpass everything.For more information, please visit

www.analog.com.